We are thrilled to share that the Canadian Agency for Drugs and Technologies in Heath (CADTH) recently announced that they are recommending the oral treatment ORLADEYO (berotralstat), for reimbursement. Private and public drug plans use CADTH’s final recommendation to help them decide what to include in their formularies, making this is a significant accomplishment. Canadian patients are now one step closer to accessing this oral treatment.

HAE Canada proudly provided a patient submission to be used to help CADTH make an informed decision. Thank you to the HAE Canada Advocacy Committee and HAE International’s Tony Castaldo (CEO) and Henrik Balle-Boysen (VP and COO) for contributing to this patient submission.

Please CLICK HERE to read BioCryst’s press release.